Clinical trials
Gastric clinical trials
Below are recruiting gastric clinical trials, each written for real people, not researchers. We’re tracking 862 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05536102RecruitingPhase 2
Surgery-plus chemo and immunotherapy for HER2-negative gastric cancer
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
ShanghaiAges 18–75 - NCT05537129Recruiting
Laparoscopic vs open stomach surgery for stomach cancer
This trial compares two ways surgeons remove the entire stomach (total gastrectomy): laparoscopic (small keyhole cuts) versus open surgery (one larger cut). It’s testing which approach is safer and works better for people with certain stages of stomach cancer.
Shanghai, Shanghai MunicipalityAges 20–80 - NCT05561907Recruiting
Endoscopic vs. surgical bypass for stomach blockage from cancer
This trial compares two ways to bypass a blockage in your stomach caused by cancer near the pancreas or duodenum. Both approaches create a new connection so food can pass through, but one uses a camera-guided tube (endoscopic) and the other is surgical. The study will see which works better for your symptoms and quality of life.
New Brunswick, New JerseyAges 18 years+ - NCT05593458RecruitingPhase 3
Stomach cancer surgery before chemo: artery-based or drip chemo
This trial compares two ways of giving chemotherapy before surgery for locally advanced stomach or stomach–esophagus cancer: chemo sent through an artery versus chemo given through an IV line. It also studies adding PD-1 immunotherapy to see which approach works better and is safer.
Hangzhou, ZhejiangAges 18–75 - NCT05618821RecruitingPhase 2
Indocyanine green dye during stomach surgery for leftover cancer
This Phase 2 study tests whether using a special light-activated dye (indocyanine green) during laparoscopic stomach surgery can improve surgical outcomes for people with remnant (leftover) stomach cancer that has not spread to distant organs. It may help surgeons better find lymph nodes while operating.
Fuzhou, FujianAges 18–75 - NCT05698992Recruiting
Rehab program after surgery for esophageal or stomach cancer
This trial tests a rehabilitation and recovery program for people with esophageal or stomach cancer who are planning curative surgery at Skåne University Hospital. It may help you regain strength and function after treatment, using a structured recovery approach.
Lund, LundAges 18 years+ - NCT05702229RecruitingPhase 2
Study of combined medicines for advanced stomach cancer with Claudin18.2
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05722275Recruiting
Predicting peritoneal spread in advanced stomach cancer
This trial uses CT scan images and a look inside the abdomen (laparoscopy) to predict whether advanced stomach cancer has spread to the lining of the abdomen (the peritoneum). It may help your care team better identify who already has peritoneal spread and who might not.
BeijingAges 18 years+ - NCT05894824RecruitingPhase 1/Phase 2
T-DXd with ramucirumab for HER2-low stomach and GEJ cancer
This trial studies T-DXd given with ramucirumab to treat stomach (gastric) or stomach–esophagus junction (GEJ) cancer that has spread or is locally advanced and is “HER2-low.” It’s mainly to test safety and early effectiveness in people whose cancer continued after first-line treatment.
Seoul, SeoulAges 19 years+ - NCT05930860Recruiting
Endoscopic treatment for certain superficial stomach growths
This trial studies how safe and effective a procedure called endoscopic submucosal dissection (ESD) is for treating certain early, superficial stomach (gastric) growths. It may be an option if your growth fits the endoscopy criteria and you are not a good candidate for stomach surgery.
RomeAges 18 years+ - NCT05956847Recruiting
Studying DNA fragments in stomach cancer tissue
This trial looks at tiny pieces of DNA found outside cells in stomach tissue to better understand how gastric (stomach) cancer starts and progresses. It may help future patients by improving how doctors study stomach cancer from biopsy and surgical samples.
Xi'an, ShaanxiAges 18–80 - NCT05975749RecruitingPhase 2
Trastuzumab, serplulimab, and chemo after stomach cancer surgery
This Phase 2 study looks at whether adding serplulimab to trastuzumab and chemotherapy after surgery can lower the chance of stomach cancer coming back. It is for people with HER2-positive stage II–III stomach adenocarcinoma who have already had curative surgery with lymph node removal.
Shanghai, Shanghai MunicipalityAges 20–80 - NCT05977998RecruitingPhase 2
Paclitaxel given during surgery for stomach cancer spread to the belly
This trial studies whether adding paclitaxel chemotherapy around the time of surgery can improve outcomes for people with stomach or gastroesophageal junction adenocarcinoma that has spread to the lining of the abdomen (peritoneum). It targets cancers confirmed by testing of belly fluid or by laparoscopy/laparotomy, and may help by treating cancer cells right at the time of surgery.
Houston, TexasAges 18 years+ - NCT05991947Recruiting
Blood test for early stomach cancer detection
This study is testing a new way to find stomach (gastric) cancer early using a simple blood test. It may help people who have just been diagnosed with stage I, II, or III stomach cancer and have not started treatment yet.
Hangzhou, ZhejiangAges 18–100 - NCT06008054RecruitingPhase 2
New drug combo for advanced gastrointestinal cancers
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
Beijing, Beijing MunicipalityAges 18–75 - NCT06008925RecruitingPhase 1/Phase 2
VG161 plus nivolumab for advanced gastric cancer
This trial tests a new combination therapy (VG161, a herpes-based virus therapy, plus nivolumab) for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two previous treatments, including a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06027242Recruiting
Glutamine supplement after stomach cancer surgery
This trial tests if taking glutamine (a nutrient) as an oral supplement helps patients recover after surgery to remove stomach cancer. It aims to see if it improves healing and quality of life.
TaipeiAges 20 years+ - NCT06035250Recruiting
AI predicts stomach cancer response to chemo before surgery
This study tests whether an AI tool can predict how well stomach cancer responds to chemotherapy before surgery. It uses CT scans and biopsy images taken before treatment starts to see if the AI can help guide future care.
BeijingAges 18 years+ - NCT06036745RecruitingPhase 2
Palizumab and SOX chemo after gastric cancer surgery
This trial tests adding palizumab (an immunotherapy) to standard SOX chemotherapy after surgery for stage IIIB-IIIC gastric or GEJ cancer. It's for people whose tumors have certain markers (MSI-H, TMB-H, or high PD-L1) that may make immunotherapy more effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06055387Recruiting
Frailty care for older stomach cancer patients after surgery
This study tests a frailty assessment and intervention program for people aged 65+ with stage II or III stomach cancer who will have surgery and chemotherapy afterward. It aims to improve recovery and quality of life.
Taoyuan, TaiwanAges 65 years+ - NCT06054906RecruitingPhase 2
Immunotherapy plus chemo before surgery for stomach cancer
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
ShanghaiAges 18 years+ - NCT06057597Recruiting
Comparing two types of gastric bypass surgery for weight loss
This trial compares a new version of gastric bypass (with a longer 150cm bypassed segment) to the standard Roux-en-Y gastric bypass to see which leads to better weight loss and health improvements. It is for people with severe obesity who are already scheduled for surgery and want to help find the best procedure.
ParisAges 18–65 - NCT06071507Recruiting
Comparing treatments for stomach blockage in pancreatic cancer
This trial compares three ways to relieve a stomach or duodenal blockage caused by pancreatic cancer: placing a stent, performing a bypass with a thin tube (endoscopy), or surgical bypass. It aims to find which option helps patients eat and feel better sooner.
ParisAges 18 years+ - NCT06091423RecruitingPhase 2
XELOX plus fruquintinib and sintilimab for stomach cancer with liver or lymph node spread
This trial tests a combination of chemotherapy (XELOX), a targeted therapy (fruquintinib), and an immunotherapy (sintilimab) to shrink stomach cancer that has spread only to the liver or retroperitoneal lymph nodes. The goal is to make the cancer removable by surgery.
NanjinAges 18–75
Hear when a new Gastric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric?
- Yes. Clin2 currently lists 862 recruiting gastric studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.